<DOC>
	<DOCNO>NCT01024647</DOCNO>
	<brief_summary>The purpose study determine increase dose and/or dose frequency certolizumab pegol ( Cimzia ) effective regain optimize response patient moderate severe Crohn 's disease .</brief_summary>
	<brief_title>Optimizing Cimzia Crohn 's Patients</brief_title>
	<detailed_description>This open label study patient moderate severe Crohn 's disease evaluate treatment option improve capture initial response regain loss response certolizumab pegol ( Cimzia ) . It 26 week open label clinical trial may extend 52 week patient respond treatment initial 26 week study . The follow dosing option test : 1 ) Re-induction ( one supplemental dose 400mg ) 2 ) Dose splitting ( 200mgQ2W ) 3 ) Dose Escalation ( 400mg Q2W . The high dose study , 400mg Q2W , use large phase III trial ( WELCOME ) without new safety signal . Efficacy safety measure monitor .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>ileal and/or colonic Crohn 's disease moderate severe Crohn 's disease short bowel syndrome ostomy antiTNF therapy within 4 week prior certolizumab therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>